Prolonged effectiveness of bepotastine besilate ophthalmic solution for the treatment of ocular symptoms of allergic conjunctivitis

Journal of Ocular Pharmacology and Therapeutics

Volumn 27, Issue 4, 2011, Pages 385-393

  Williams, Jon I ^a   Kennedy, Kathryn S ^b   Gow, James A ^a   Torkildsen, Gail L ^c   Abelson, Mark B ^d,e,f   Gomes, Paul J ^d   McNamara, Timothy R ^a  

^a ISTA Pharmaceuticals Inc   (United States)

^b Statistics and Data Corporation   (United States)

^c Andover Eye Associates   (United States)

^d Ora Inc   (United States)

^e SCHEPENS EYE RESEARCH INSTITUTE   (United States)

^f HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETOTASTINE; EYE DROPS; PLACEBO;

ADULT; ALLERGIC CONJUNCTIVITIS; ANXIETY DISORDER; ARTICLE; CHEMOSIS; CONJUNCTIVA ALLERGEN CHALLENGE; CONJUNCTIVAL HYPEREMIA; DRUG EFFICACY; DRUG SAFETY; DYSGEUSIA; EPIPHORA; EPISCLERITIS; EYE IRRITATION; EYELID DISEASE; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; LYMPHADENOPATHY; MAJOR CLINICAL STUDY; MALE; OCULAR PRURITUS; PROVOCATION TEST; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; RHINOPHARYNGITIS;

ADOLESCENT; ADULT; AGED; ANTI-ALLERGIC AGENTS; CHILD; CONJUNCTIVA; CONJUNCTIVITIS, ALLERGIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; HYPEREMIA; MALE; MIDDLE AGED; OPHTHALMIC SOLUTIONS; PIPERIDINES; PROSPECTIVE STUDIES; PRURITUS; PYRIDINES; TIME FACTORS; YOUNG ADULT;

EID: 79961188988     PISSN: 10807683     EISSN: 15577732     Source Type: Journal    
DOI: 10.1089/jop.2011.0005     Document Type: Article

References (46)

1. Abelson, M.B., Smith, L., and Chapin, M. Ocular allergic disease: Mechanisms, disease subtypes, treatment. Ocul. Surf. 1:127-149, 2003. (Pubitemid 41263901)
2. Abelson, M.B., and Allansmith, M.R. Histamine in the eye. In: Silverstein A, O'Connor G, eds. Immunology and Immunopathology of the Eye. New York: Masson Publishing, 1979:362-364.
3. Leonardi, A. Role of histamine in allergic conjunctivitis. Acta Ophthalmol. Scand. Suppl. 230:18-21, 2000.
4. Leonardi, A. Emerging drugs for ocular allergy. Expert Opin. Emerg. Drugs. 10:505-520, 2005. (Pubitemid 41176284)
5. Sakai, A., Kikuchi, M., Yato, N., et al. Inhibitory effect of betotastine besilate on antigen-induced airway eosinophil infiltration and peripheral blood eosinophilia in mice. Arzneimittelforschung 47:954-958, 1997. (Pubitemid 27357020)
6. Ukai, K., Takeuchi, M., and Masuda, S. Clinical pharmacological study of antiallergic agent TAU-184 (bepotastine besilate)-the effect on counting of eosinophils in nasal discharge, and the patency improvement of nasal cavity [in Japanese]. J. Clin. Ther. Med. 13:1401-1412, 1997.
7. Yato, N., Murata, T., Saito, N., et al. Anti-allergic activity of betotastine besilate (TAU-284), a new anti-allergic drug [in Japanese]. Folia Pharmacol. Jpn. 110:19-29, 1997. (Pubitemid 27294924)
8. Ueno, M., Inagaki, N., Nagai, H., and Koda, A. Antiallergic action of betotastine besilate (TAU-284) in animal models: A comparison with ketotifen. Pharmacology 57:206-214, 1998. (Pubitemid 28423031)
9. Honda, H., Murata, K., Hamazaki, A., et al. Inhibitory effect on anaphylactic reaction and histamine-antagonizing action [in guinea pigs] of betotastine besilate (TAU-284), a novel anti-allergic drug [in Japanese]. Jpn. Pharmacol. Ther. 25: 879-888, 1997.
10. Sakamoto, O., Okanari, E., and Ueno, H. Suppression effects of the novel drug betotastine besilate (TAU-284) on experimental asthmatic reactions in guinea pigs [in Japanese]. Jpn. J. Pharmacol. Ther. 25:889-894, 1997.
11. Andoh, T., and Kuraishi, Y. Suppression by bepotastine besilate of substance P-induced itch-associated responses through the inhibition of the leukotriene B4 action in mice. Eur. J. Pharmacol. 547:59-64, 2006. (Pubitemid 44373903)
12. Kaminuma, O., Ogawa, K., Kikkawa, H., et al. A novel antiallergic drug, betotastine besilate, suppresses interleukin-5 production by human peripheral blood mononuclear cells. Biol. Pharm. Bull. 21:411-413, 1998. (Pubitemid 28216984)
13. Ohashi, Y. Immunological study of a second-generation antihistamine drug-the effects of bepotastine besilate on cytokine production from the peripheral blood mononuclear cells in cedar pollen allergy patients [in Japanese]. Prog. Med. 24:157-159, 2004.
14. Maruta, H., Nagata, M., Koga, H., and Tajiri, S. Clinical evaluation of bepotastine besilate (Talion tablets) on chronic urticaria [in Japanese]. J. New Rem. Clin. 53:576-582, 2004.
15. Takahashi, H., Ishida-Yamamoto, A., and Iizuka, H. Effects of bepotastine, cetirizine, fexofenadine, and olopatadine on histamine-induced wheal-and flare-response, sedation, and psychomotor performance. Clin. Exp. Dermatol. 29:526-532, 2004. (Pubitemid 39278201)
16. Ishibashi, Y., Harada, S., and Niimura, M. Early phase II study of TAU-284 (betotastine besilate) on chronic urticaria [in Japanese]. J. Clin. Ther. Med. 13:1199-1215, 1997.
17. Ishibashi, Y., Harada, S., and Niimura, M. Late phase II study of TAU-284 (betotastine besilate) on chronic urticaria - optimal dose finding study by double-blind technique [in Japanese]. J. Clin. Ther. Med. 13:1237-1257, 1997.
18. Horikawa, T., Harada, S., and Tamura, S. The clinical efficacy of bepotastine besilate in relation to senile dermal pruritus: Usage testing [in Japanese]. Sci. Skin. 4:475-480, 2005.
19. Kawana, S., Niimi, Y., and Higashi, N. Kikuchi, I. Effectiveness and safety investigation of bepotastine besilate (Talion tablets) in patients with atopic dermatitis [in Japanese]. J. New Rem. Clin. 54:1325-1331, 2005.
20. Ohta, N., Akasuka, N., Saito, F., et al. The effect of prophylactic treatment with bepotastine in patients with Japanese cedar pollinosis [in Japanese]. Pract. Otol. 95:531-537, 2002. (Pubitemid 35415967)
21. TALION [package insert]. Osaka, Japan: Tanabe Seiyaku Co., Ltd., 2009.
22. Abelson, M.B., Torkildsen, G.L., Williams, J.I., et al. A single center, double-masked, randomized, placebo-controlled evaluation of the onset and duration of action of the ophthalmic antihistamine bepotastine besilate 1.0% and 1.5% in the conjunctival allergen challenge model of allergic conjunctivitis. Clin. Ther. 31:1908-1921, 2009.
23. Macejko, T.T., Bergmann, M.T., Williams, J.I., et al. Multicenter clinical evaluation of bepotastine besilate ophthalmic solution 1.0% and 1.5% to treat allergic conjunctivitis Am. J. Ophthalmol. 150:122-127, 2010.
24. Abelson, M.B., and Spitalny, L. Combined analysis of two studies using the conjunctival allergen challenge model to evaluate olopatadine hydrochloride, a new ophthalmic antiallergic agent with dual activity. Am. J. Ophthalmol. 125:797-804, 1998. (Pubitemid 28283741)
25. Abelson, M.B. Evaluation of olopatadine, a new ophthalmic antiallergic agent with dual activity, using the conjunctival allergen challenge model. Ann. Allergy Asthma Immunol. 81:211-218, 1998. (Pubitemid 28464704)
26. Abelson, M.B., Chapin, M.J., Kapik, B.M., and Shams, N.B. Efficacy of ketotifen fumarate 0.025% ophthalmic solution compared with placebo in the conjunctival allergen challenge model. Arch. Ophthalmol. 121:626-630, 2003. (Pubitemid 36554464)
27. Abelson, M.B., Gomes, P., Crampton, H.J., et al. Efficacy and tolerability of ophthalmic epinastine assessed using the conjunctival antigen challenge model in patients with a history of allergic conjunctivitis. Clin. Ther. 26:35-47, 2004. (Pubitemid 38241521)
28. Abelson, M.B., Gomes, P.J., Pasquine, T., et al. Efficacy of olopatadine ophthalmic solution 0.2% in reducing signs and symptoms of allergic conjunctivitis. Allergy Asthma Proc. 28:427-433, 2007.
29. Torkildsen, G.L., Williams, J.I., Gow, J.A., et al. Bepotastine besilate ophthalmic solution for the relief of nonocular symptoms provoked by conjunctival allergen challenge. Ann. Allergy Asthma Immunol. 105:57-64, 2010.
30. BEPREVE [package insert]. Irvine, CA ISTA Pharmaceuticals, Inc. 2010.
31. Rosner, B. Comparisons of specific groups in one-way ANOVA, In: Rosner, B., ed. Fundamentals of Biostatistics, 6th ed. Boston: Duxbury Press; 2005; p. 564-582.
32. [No authors listed] Drugs for allergic disorders. Med. Lett. 8:9-18, 2010.
33. Tanaka, T., Miyazaki, S., and Ishikawa, K. The usefulness of Talion in relation to nasal congestion in allergic rhinitis [in Japanese]. Prog. Med. 24:2037-2044, 2004.
34. Kimitsuki, T., Horinouchi, K., Toyama, K., et al. Investigation of the effectiveness of bepotastine besilate (Talion tablets) on patients with ear itchiness. Jibi Rinsho. 51:131-136, 2005.
35. Shimochi, H. SNJ-1773 Phase II trial-clinical pharmacology trial for patients with allergic conjunctivitis during the free interval. Senju Clinical Trial Report SNJ-TO-03, 2004.
36. Shimoji, H. SNJ-1773 Phase 1 clinical study (repeated instillation study) Senju Clinical Study Report SNJ-TO-02, 2003.
37. Ikemura, H. SNJ-1772 Phase II trial. Exploratory test on allergic conjunctivitis. Senju Study Summary Report SNJ-TO-04, 2005.
38. Schatz, M. A survey of the burden of allergic rhinitis in the USA. Allergy 62 Suppl 85:9-16, 2007. (Pubitemid 47561568)
39. Sisler, H.A. One-way flow in the lacrimal drainage system: Determinants from the basic sciences. Ann. Ophthalmol. 14:76-77, 1982. (Pubitemid 12191829)
40. Spangler, D.L., Abelson, M.B., Ober, A., and Gomes, P.J. Randomized, double-masked comparison of olopatadine ophthalmic solution, mometasone furoate monohydrate nasal spray, and fexofenadine hydrochloride tablets using the conjunctival and nasal allergen challenge models. Clin. Ther. 25:2245-2267, 2003. (Pubitemid 37076317)
41. Abelson, M.B., and Loeffler, O. Conjunctival allergen challenge: Models in the investigation of ocular allergy. Curr. Allergy Asthma Rep. 3:363-368, 2003. (Pubitemid 38914984)
42. Abelson, M.B., Chambers, W.A., and Smith, L.M. Conjunctival allergen challenge: A clinical approach to studying allergic conjunctivitis. Arch. Ophthalmol. 108:84-88, 1990. (Pubitemid 20031417)
43. Guest, J.F., Davie, A.M., Ruiz, F.J., and Greener, M.J. Switching asthma patients to a once-daily inhaled steroid improves compliance and reduces healthcare costs. Prim. Care Respir. J. 14:88-98, 2005. (Pubitemid 40410057)
44. Schenker, H., Maloney, S., Liss, C., et al. Patient preference, efficacy, and compliance with timolol maleate ophthalmic gel-forming solution versus timolol maleate ophthalmic solution in patients with ocular hypertension or open-angle glaucoma. Clin. Ther. 21:138-147, 1999. (Pubitemid 29106696)
45. Claxton, A.J., Cramer, J., and Pierce, C. A systematic review of the associations between dose regimens and medication compliance. Clin. Ther. 23:1296-1310, 2001. (Pubitemid 32804122)
46. Granger, A.L., Fehnel, S.E., Hogue, S.L., et al. An assessment of patient preference and adherence to treatment with Wellbutrin SR: A web-based survey. J. Affect Disord. 90:217-221, 2006. (Pubitemid 43183531)